Release Date: January 11, 2023
Expiration Date: January 11, 2024
Activity Overview
Graft-versus-host disease (GVHD) is a serious complication of hematopoietic stem cell transplantation (HSCT), leading to potentially life-threatening sequelae. Recent innovations in prophylaxis and active therapy have created dramatic impacts on the management of GVHD across both the acute and chronic settings. However, optimal treatment for GVHD continues to be dependent on various patient- and disease-related factors.
This on-demand symposium webcast is designed to provide clinicians with up-to-date understanding of prophylaxis and management of acute and chronic GVHD following an allogeneic stem cell transplant. Through didactic presentations and challenging case-based discussions, participants will be given the best practices for developing a comprehensive approach to this serious complication.
This educational activity is an archive of the live hybrid symposium held on December 9, 2022.
Target Audience
This activity is directed toward a global audience of medical oncologists, hematologic oncologists, hematologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of GVHD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the pathological mechanisms of acute and chronic GVHD underlying the rationale for therapeutic approaches to prevent and treat these post-transplant complications
- Evaluate the latest clinical evidence for therapeutic strategies investigated for the prevention and treatment of acute/chronic GVHD
- Apply strategies to promote the timely recognition and mitigation of treatment-related toxicities in patients at risk of developing GVHD or who are treated for GVHD
- Translate evidence-based approaches for the prophylaxis and treatment of acute and chronic GVHD into personalized treatment plans for patients after transplantation to prevent or manage these post-transplant complications
Corey Cutler, MD, MPH, FRCPC
Associate Professor of Medicine
Harvard Medical School
Medical Director, Adult Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consultant: Advisory Board/Consultant for: Bristol Myers Squibb, CareDx, Cimeio Therapeutics, CSL Behring, CTI BioPharma, Deciphera Pharmaceuticals, Editas Medicine, Equillium, Incyte Corporation, Janssen, Jazz Pharmaceuticals, Mallinckrodt, Omeros, Oxford Immune Algorithmics, Pfizer, Sanofi; Other: Data and Safety Monitoring Board (DSMB): AlloVir, Angiocrine Bioscience, BioLineRx, Da Volterra, Pluristem Therapeutics.
Sergio Giralt, MD, FACP, FASTCT
Professor of Medicine
Weill Cornell Medical College
Melvin Berlin Family Chair in Myeloma Research
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Disclosures: Grant/Research Support: Actinium Pharmaceuticals, Amgen, Celgene, Johnson and Johnson, Miltenyi Biotec, Sanofi, Takeda Pharmaceutical; Other: Advisory boards for: Actinium Pharmaceuticals, Amgen, Celgene, Jazz Pharmaceuticals, Johnson & Johnson, Kite Pharmaceuticals, Novartis, Sanofi, Takeda Pharmaceutical.
Catherine Lee, MD
Associate Professor of Medicine
Division of Hematology & Hematologic Malignancies
The University of Utah Transplant and Cellular Therapy Program at Huntsman Cancer Institute and Primary
Children's Hospital
Salt Lake City, UT
Disclosures: Grant/Research Support: Incyte Corporation; Consultant: Bristol Myers Squibb, CareDx, Fresenius Kabi, Fresenius Medical Care, Incyte Corporation, Kadmon, Kite Pharma; Speakers’ Bureau: Kite Pharma; Other: Incyte Corporation, study steering committee.
Doris M. Ponce, MD
Associate Professor of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Incyte Corporation.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.